CTLA4 and intrahepatic cholangiocarcinoma: Our data suggest that CTLA-4 overactivation in hepatolithiasis-related ICC is likely the predominant factor involved in sustaining the inhibitory immune environment, providing a promising therapeutic target for such patients.